

### **HHS Public Access**

Author manuscript *Acad Pediatr*. Author manuscript; available in PMC 2021 August 05.

Published in final edited form as:

Acad Pediatr. 2015; 15(2): 149–157. doi:10.1016/j.acap.2014.10.006.

## Effect of Provider Prompts on Adolescent Immunization Rates: A Randomized Trial

Peter G. Szilagyi, MD, MPH, Janet R. Serwint, MD, Sharon G. Humiston, MD, MPH, Cynthia M. Rand, MD, MPH, Stanley Schaffer, MD, MS, Phyllis Vincelli, BS, Nui Dhepyasuwan, MEd, Aaron Blumkin, MS, Christina Albertin, MPH, BSN, C. Robinette Curtis, MD, MPH Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY (Dr Szilagyi, Dr Rand, Dr Schaffer, Ms Vincelli, Mr Blumkin, Ms Albertin, Ms Vincelli); Department of Pediatrics, Johns Hopkins University, Baltimore, Md (Dr Serwint); Division of Emergency and Urgent Care, Department of Pediatrics, Children's Mercy Hospitals and Clinics, Kansas City, Mo (Dr Humiston); Academic Pediatric Association (Ms Dhepyasuwan); and Centers for Disease Control and Prevention, Atlanta, Ga (Dr Curtis)

#### Abstract

**Objective:** Adolescent immunization rates are suboptimal. Experts recommend provider prompts at health care visits to improve rates. We assessed the impact of either electronic health record (EHR) or nurse- or staff-initiated provider prompts on adolescent immunization rates.

**Methods:** We conducted a randomized controlled trial, allocating practices in 1 of 2 practicebased research networks (PBRN) to provider prompts or standard-of-care control. Ten primary care practices participated, 5 intervention and 5 controls, each matched in pairs on urban, suburban, or rural location and practice type (pediatric or family medicine), from a PBRN in Greater Rochester, New York (GR-PBRN); and 12 practices, 6 intervention, 6 controls, similarly matched, from a national pediatric continuity clinic PBRN (CORNET). The study period was 1 year per practice, ranging from June 2011 to January 2013. Study participants were adolescents 11 to 17 years attending these 22 practices; random sample of chart reviews per practice for baseline and postintervention year to assess immunization rates (n = 7,040 total chart reviews for adolescents with >1 visit in a period). The intervention was an EHR prompt (4 GR-PBRN and 5 CORNET practice pairs) (alert) that appeared on providers' computer screens at all office visits, indicating the specific immunizations that adolescents were recommended to receive. Staff prompts (1 GR-PBRN pair and 1 CORNET pair) in the form of a reminder sheet was placed on the provider's desk in the exam room indicating the vaccines due. We compared immunization rates, stratified by PBRN, for routine vaccines (meningococcus, pertussis, human papillomavirus, influenza) at study beginning and end.

**Results:** Intervention and control practices within each PBRN were similar at baseline for demographics and immunization rates. Immunization rates at the study end for adolescents who were behind on immunizations at study initiation were not significantly different for intervention

Address correspondence to Peter G. Szilagyi, MD, MPH, Department of Pediatrics, UCLA, 10833 LeConte MC 175217, 12-358 MDCC, Los ANgeles, CA 90095 (p\_szilagyi@mednet.ucla.edu).

During this study, Dr Humiston was a consultant to Immunization Action Coalition.

The other authors declare that they have no conflict of interest.

versus control practices for any vaccine or combination of vaccines. Results were similar for each PBRN and also when only EHR-based prompts was assessed. For example, at study end, 3-dose human papillomavirus vaccination rates for GR-PBRN intervention versus control practices were 51% versus 53% (adjusted odds ratio 0.96; 95% confidence interval 0.64–1.34); CORNET intervention versus control rates were 50% versus 42% (adjusted odds ratio 1.06; 95% confidence interval 0.68–1.88).

**Conclusions and Relevance::** In both a local and national setting, provider prompts failed to improve adolescent immunization rates. More rigorous practice-based changes are needed.

#### Keywords

adolescent immunization; EHR; HPV; influenza; meningococcal; outreach; provider prompt; Tdap

Since 2005, adolescent immunization delivery has become increasingly important but also more complex, the result of age-specific recommendations of vaccines to prevent tetanus, diphtheria, pertussis (Tdap), meningococcal (MCV4), and human papillomavirus (HPV) infections and universal recommendation of influenza vaccination for all persons, including teens.<sup>1,2</sup> Unfortunately, despite substantial research, publicity, and efforts by experts to optimize adolescent immunization delivery, immunization rates are suboptimal.<sup>2,3</sup> In 2012, 85% of adolescents aged 13 to 17 years had received Tdap, 74% had received MCV4, and  $\approx$ 40% had received an influenza vaccination<sup>4</sup>; 54% of girls (and 21% of boys) aged 13 to 17 years had received 3 doses.<sup>2</sup> Finally, some disparities exist, with minority adolescents having lower completion rates of HPV vaccine and lower rates of influenza vaccination.<sup>5–8</sup>

Experts, including the Task Force on Community Preventive Services,9,10 recommend that primary care practices use one or more strategies to optimize adolescent immunization delivery. One recommended strategy is health care provider prompts to reduce missed opportunities for vaccinations.<sup>11,12</sup> Provider prompts, or alerts, are produced by nurse/staff, or by the electronic health record (EHR) at the time of patient visits to remind health care providers to administer age-appropriate vaccinations. Few primary care practices use provider prompts for adolescent immunizations as a result of implementation barriers such as complexity and cost.<sup>13</sup> Further, few studies have evaluated provider prompts' effectiveness among adolescent populations, and those that have reported mixed results. One study showed no benefit of prompts for influenza vaccinations among children and adolescents with asthma,<sup>14</sup> while a recent study in a hospital-based primary care system using a single EHR showed benefit for HPV vaccination initiation but not subsequent doses. <sup>15</sup> Thus, although some experts recommend provider prompts for a variety of preventive measures,<sup>16–20</sup> little evidence supports their effectiveness for adolescent immunizations. Of note, earlier studies demonstrated that nurse/staff prompts had variable success in reducing missed opportunities for childhood vaccinations.<sup>11,12,21-24</sup>

We conducted a randomized controlled trial in 2 practice-based research networks (PBRNs), an upstate New York network and a national network of pediatric continuity clinics, to evaluate the impact of provider prompts on adolescent immunization rates. We used community-based participatory research methods for practitioners to reach a consensus on

the intervention to be studied, which converged on provider prompts, and then conducted the intervention in both PBRNs. We hypothesized that provider prompts would improve adolescent immunization rates.

#### Methods

#### Setting

The study was based in both a local and a national PBRN. The Greater Rochester PBRN (GR-PBRN)<sup>25</sup> consists of 85 primary care practices, including 44 pediatric and 14 family medicine practices serving >80% of all children in the Monroe County, New York, region, which has a population of 750,000. The national Continuity Clinic Research Network (CORNET) consists of 73 pediatric continuity clinics in 36 states serving over 683,000 children and adolescents; many are large hospital-based continuity clinics.

#### **Study Design**

Using concepts of diffusion theory outlined by Rogers,<sup>26</sup> we performed a 3-part mixedmethods study<sup>27</sup> to 1) determine a consensus-driven, practice-based strategy to improve adolescent immunization rates, 2) test the strategy in 2 PBRNs, and 3) evaluate practitioner perceptions of the interventions.

**Selection of a Practice-based Intervention**—We first conducted a mixed-methods mailed/online survey of primary care practices plus qualitative key informant interviews of a subset of practices in the 2 PBRNs to: 1) ascertain which of the recommended adolescent immunization strategies practitioners were using and would be interested in adopting (reported previously<sup>28</sup>); 2) develop consensus about which specific intervention to evaluate on the basis of practitioner perception of the intervention's feasibility, effectiveness, and sustainability; and 3) identify practices that were interested in participating in intervention evaluation. Two-thirds of GR-PBRN and three-quarters of CORNET practices selected provider immunization prompts delivered either by nurse/staff during patient visits, or delivered by EHR for study.

**Evaluation of Provider Prompts**—We conducted a randomized controlled trial, stratified by PBRN, to test the impact of provider prompts on increasing adolescent immunization rates. Intervention practices within each PBRN were matched with control practices in pairs by suburban, urban, or rural status and practice type (pediatrics or family medicine). The 12-month randomized controlled trial spanned June 6, 2011, to June 5, 2012 (GR-PBRN), and September 20, 2011, to January 30, 2013 (CORNET; intervention/control practice pairs had staggered starts over a 4-month period, but for each practice within an intervention/control pair of CORNET practices the study time period was the same).

**Assessment of Practitioner Perceptions of the Intervention**—After the intervention, we conducted a qualitative phone interview of one practitioner from all intervention practices to assess perceptions of feasibility, acceptability, and sustainability of the provider prompts. We used constructs from diffusion theory as the conceptual

framework.<sup>26</sup> Two authors [SH, PV (GR-PBRN); SH, ND (CORNET)] performed, documented, and analyzed interviews.

The research subjects review board of the University of Rochester approved all 3 study components; the 14 CORNET sites required additional institutional review board approval. Parent and patient informed consents were not required because the intervention involved a practice-based intervention recommended for general use.<sup>9</sup>

#### Participants

**Primary Care Practices and Randomization**—Fourteen GR-PBRN and 15 CORNET practices agreed, before randomization, to participate in the randomized controlled trial intervention (Figure). Our power calculation called for 6 pairs (12 sites) per PBRN to be able to detect an increase of 10 percentage points (40% to 50%) in immunization rates with 80% power, an average of 160 patients per practice, a 2-tailed alpha of 5% and an intraclass correlation (ICC) of 0.01 (or 13 percentage points with ICC = 0.02); an ICC of 0.01 to 0.02 is typical for primary care trials. Within the GR-PBRN, we created practice pairs: 4 suburban pediatric, 1 rural family medicine, and 1 urban community health center. The community health center pair was excluded because the intervention practice could not implement the intervention, leaving 5 practice pairs. Within CORNET we created 5 urban pediatric pairs and 1 rural pediatric pair of practices. Using Stata 12.1, one author (AB) randomly assigned practices within each PBRN and practice pair to be an intervention or a standard of care control practice. No practice used provider prompts at baseline for adolescent immunizations.

**Subjects**—The target population was all adolescents aged 11 to 17 years who were enrolled in a participating practice during the year before the intervention. For the qualitative postintervention survey, subjects were the practitioners.

#### Study Interventions

#### Identifying Adolescents Eligible for Immunizations or Preventive Visits-

Adolescents were considered eligible for Tdap, MCV4, or HPV vaccine based on 2010 Advisory Committee on Immunization Practices guidelines:<sup>5,29</sup> Tdap if no prior Tdap or Td vaccination within 2 years (most practices used this time frame between Tdap and Td vaccines); MCV4 if no prior vaccination; HPV vaccine for girls [first HPV vaccination (HPV<sub>1</sub>) if none prior, HPV<sub>2</sub> if >60 days from HPV<sub>1</sub>, and HPV<sub>3</sub> if >24 weeks from HPV<sub>1</sub> and >12 weeks from HPV<sub>2</sub>], and influenza vaccine if none received that season. We did not include catch-up vaccinations (eg, varicella vaccine<sup>30</sup>).

**EHR-based Prompts**—We worked with EHR personnel to program EHRs to display a provider prompt (alert) on the initial screen that health care providers viewed upon opening each patient's electronic medical chart. Although EHR prompts varied slightly in appearance, screen location, and method to document refusals, all prompts used the same algorithm and displayed a list of vaccines due at that visit. Prompts did not generally show prior vaccinations and did not include standing orders. We worked with 9 EHR vendors, 4 for the GR-PBRN and 5 for CORNET practices. EHRs were programmed to display

prompts at all visits, not just preventive visits. In 3 of 4 EHR intervention practices from the GR-PBRN, the EHR prompt was only used for adolescent (not child) immunizations; in the remaining EHR practice, immunization prompts were activated for all ages, but results were analyzed only for adolescent immunizations. In CORNET's EHR intervention practices, immunization prompts were turned on for all ages. Two CORNET intervention practices transitioned to EHRs during the study and performed nurse/staff prompts for several months until EHR prompts were implemented; these practices were allocated to the EHR group. For each intervention practice, we provided one or two 1-hour educational sessions to inform providers about EHR-based prompts. On the basis of participating practitioners' preferences and practice patterns, providers could elect to follow or ignore prompts.

**Nurse/Staff Prompts (1 Practice per PBRN)**—At 2 intervention practices, practitioners preferred nurse/staff prompts because they lacked EHRs that could be programmed to deliver prompts. For these practices, we delivered 1 or 2 educational sessions to physicians and nurses/staff. We described the importance of immunizations and provided a nurse/staff protocol to: 1) review immunization records for every adolescent at each visit; 2) list immunizations due at each visit onto a sheet; and 3) display vaccine information statement forms.

**Follow-up Telephone Calls**—We conducted monthly telephone calls with intervention practices to assess progress, address concerns, and engage practitioners in group discussions and problem solving (eg, strategies during busy periods). We encouraged practices to select a small number of charts to review for missed opportunities as a process metric; of note, few practices complied as a result of limited time and staff to perform chart reviews. We used this "low-touch" approach on the basis of practitioner preferences and to optimize sustainability.

**Controls**—Adolescents in control practices received standard of care, which did not include prompts.

#### **Postintervention Survey**

For each intervention practice, a physician leader and an office manager were interviewed by phone by one investigator (SH), using a predefined outline of questions that assessed feasibility, acceptability, and sustainability of prompts. Respondents were sent the questions before the interview and were also asked open-ended questions to elaborate upon their answers.

#### **Outcome and Process Measures**

**Patient Information, Missed Opportunities, and Immunization Rates**—For each practice, we obtained the practice denominator at 2 points in time: at the start of the intervention to assess the 12-month baseline period, and 1 year later to assess the 12-month intervention period. The denominator for the baseline period was defined as adolescents who had >1 visit of any kind within the 12-month period and were 11 to 17 years at the start of the time period. The denominator for the intervention period was adolescents with >1 visit during the intervention period, regardless of visits during the baseline period. We then

randomly selected 160 adolescents from each practice for standardized chart reviews, at both the start and end. Our research assistants reviewed GR-PBRN charts; for CORNET practices across 11 states, a provider or nurse champion at each site was trained to review the charts. All chart reviews were recorded on paper and sent to Rochester-based research staff for double data entry and analysis.

**Measures**—Main outcomes were receipt of recommended Tdap, MCV4, HPV<sub>1,2,3</sub>, and influenza vaccines on or after the 11th birthday, as well as combinations of these vaccines. A secondary immunization outcome was time to vaccination in days since the 11th birthday. An additional outcome was missed opportunities, defined as visits in which an adolescent was due for a vaccination but did not receive the vaccine. Missed opportunities were further coded as refusals, deferred, other, or no notation in the chart.

Answers to the postintervention qualitative phone interviews were reviewed by 3 authors (SH, PV, CA), with interpretive differences resolved through discussion.

#### Statistical Analyses

The primary independent variable was group assignment (intervention vs control). We also performed an analysis limited to EHR practice pairs. All analyses were stratified by PBRN. We first used descriptive statistics to compare baseline provider/patient factors and immunization rates for intervention versus control practices. Because we had randomized practice pairs (intervention/control), we accounted for multiple levels of nonindependence and clustering (by intervention/control pairs, and then by practice). We used a multilevel mixed-effect logistic regression model with robust standard errors, with patients nested within practices, and covariates for pair assignment, study time period, intervention term portrays how much more (or less) the intervention group's odds of immunization increased compared to the control group's odds of immunization. For time to event analyses, we used a stratified Cox model, stratifying on paired practices, and robust standard errors, with just the study time period, intervention assignment, and an interaction between the 2, within the model. We estimated hazard ratios for receipt of vaccinations. We used StataMP software, version 13.1.<sup>31</sup>

#### Results

#### **Randomization and Baseline Characteristics**

The Figure shows randomization and assessment processes. For the GR-PBRN, of 88 practices that responded to the survey, 43 practices expressed interest in being randomized to an intervention, and 31 were excluded before randomization (>50 miles from Rochester, New York; <500 adolescents; already using EHR prompts; or EHRs not programmable for prompts and not willing to use nurse prompts). The 12 remaining practices were eligible for randomization and were stratified by urban, suburban, or rural residents and pediatric or family medicine practices. They were subsequently randomly allocated within pairs to intervention or control groups. For CORNET, of 78 clinics that responded to the survey, 41 expressed interest in being randomized to an intervention, 12 were excluded for ineligibility

(<500 adolescents, already using EHR prompts), 29 were eligible, and we selected 12 (6 pairs) that were geographically disparate for randomization. Table 1 shows practice and patient characteristics of intervention versus control groups stratified by PBRN. In the GR-PBRN group, intervention practices had a slightly higher percentage of publicly insured adolescents; in the CORNET group, intervention practices had a slightly higher percentage of white adolescent patients.

#### Immunization Rates

Table 2 shows immunization rates at baseline and at the end of the study period, stratified by PBRN. Baseline immunization rates closely mirrored national rates.<sup>32</sup> The adjusted odds ratio represents the ratio of the odds (postintervention period vs baseline immunization rates) for intervention versus control practices—that is, the change in immunization rates due to the intervention. Table 2 reveals 3 key findings. First, baseline immunization rates were high for 2 vaccines (Tdap and MCV4) and quite low for HPV and influenza vaccinations. Second, vaccination rates increased slightly from baseline to end of study period for both control and intervention practices (ie, secular trends). Third, the intervention did not appear to increase immunization rates in either PBRN for any of the individual vaccines or for combinations. That is, adjusted odds ratios were not significantly greater than 1.0.

We also used survival analysis to assess time to HPV vaccination as a more sensitive measure of the intervention effect (Table 3). In both PBRNs, the intervention had no effect on the time from start of the intervention period to receiving any of the HPV vaccine doses or to being fully vaccinated, with one exception: in the GR-PBRN group, intervention subjects were 124% more likely to receive HPV<sub>2</sub> at any given time than adolescents from control practices (median of 54 days vs 79 days after HPV<sub>1</sub>).

#### **Missed Opportunities**

Provider prompts were designed to improve immunization rates by reducing missed opportunities for immunizations. Table 4 shows the impact of the intervention on visits with missed opportunities (ie, visits as the unit of analysis) and on the percentage of adolescents who had a missed opportunity. With one exception, the intervention did not improve missed opportunity rates. Within the GR-PBRN, the intervention reduced missed opportunities for HPV vaccination by 18% (adjusted incident risk ratio 0.82; 95% confidence interval 0.72–0.94). We also examined simultaneous missed opportunities (ie, visits during which some but not all eligible vaccines were administered), and we found no differences between intervention and control groups (not shown in Table 4).

#### **Monthly Telephone Calls**

Many practices found it challenging to participate on the monthly calls. For the GR-PBRN, we conducted 9 calls over the 12-month study period, and the participation rate among the 5 intervention practices was as follows: 5 sites represented (4 calls), 3 sites (4 calls), and 2 sites (1 call). For the CORNET PBRN (6 sites) we conducted 12 calls over the 12-month study period, and the participation rate was as follows: 6 sites (1 call), 5 sites (2 calls), 4 sites (1 call), 3 sites (4 calls), 2 sites (3 calls), and 1 site (1 call).

#### Refusals

Because provider prompts might have caused more discussion of vaccinations but also more parental refusals, we assessed parental refusal rates by medical record review (Table 4). Parent refusals were not different in intervention versus control groups.

#### **Practitioner Perception of Intervention**

Before analyzing data on intervention impact, we interviewed providers from the 11 intervention practices to assess perceptions of the intervention's impact. Interestingly, providers from all 11 practices believed prompts were effective in reducing missed opportunities and improving immunization rates, and nearly all respondents wished to continue using prompts. However, most respondents also stated that providers ignored prompts when practices were particularly busy. Respondents reported varied practical barriers to prompts, including prompt errors (particularly early on for EHR practices as a result of incomplete vaccine records), added time for documenting refusals, time constraints for nurses for nurse-prompt practices, and lack of complete intervention acceptance by all practice members, including physicians and staff.

#### Discussion

In this randomized controlled trial conducted in 2 PBRNs, we found that provider prompts at office visits failed to improve adolescent immunization rates, despite the fact that practitioners selected provider prompts as the strategy most likely to be effective, feasible, and sustainable to raise adolescent immunization rates; that the prompts were generally performed by the EHR, ensuring that they were delivered; and that on regular conference calls and a postintervention phone interview, virtually all providers believed the prompts were effective in reducing missed opportunities and improving adolescent immunization rates.

#### **Provider Prompts and Adolescent Immunizations**

In 1996, we published results of a randomized trial in 2 urban practices to reduce missed opportunities for childhood vaccinations by using nurse/staff-generated paper prompts that listed immunizations needed at the time of office visits.<sup>21</sup> The intervention reduced missed opportunities slightly, but not enough to raise immunization rates. The major barrier was that nurses/staff failed to place the prompts consistently on the paper medical charts. Over the past 15 years, the emergence of EHRs has revolutionized primary care,<sup>33</sup> and the concept of provider prompts/alerts has emerged to facilitate delivery of recommended services such as immunizations at the time of visits.<sup>14–20,34</sup> Many EHR systems are developing such alerts. Unfortunately, our current study, conducted in 21 practices across 2 PBRNs, had a similar outcome to the 1996 study: prompts for adolescent immunizations did not improve immunization rates, even within the EHR group. Although in our prior study the barrier was the delivery of the prompts, the barrier in the current study was that providers did not act on prompts sufficiently to increase immunization rates.

#### Improving Effectiveness of Provider Prompts

Provider prompts should represent low-hanging fruit for improving quality of care because they capitalize on patients already being in providers' offices and because prompts can be programmed to reflect guideline-based care.<sup>15,16,18–20</sup> A recent report showed that if missed opportunities for HPV vaccination were eliminated, HPV vaccination rates could rise to >90%.<sup>8</sup> Another study of children with asthma found that if missed opportunities for influenza vaccination were eliminated, influenza vaccination rates substantially.<sup>35</sup> The key to provider prompts is to ensure that providers adhere to them. Unfortunately, other studies have also found that prompts can fail to generate desired improvement in care as a result of providers not believing in the accuracy of the prompts, not heeding the prompts, forgetting the prompts, or feeling "prompt fatigue."<sup>18</sup> In our study, we did not notice any time trends in missed opportunities, suggesting that prompt fatigue may have been less important than providers simply ignoring prompts.

Because EHRs are increasingly implementing prompts, it is important to evaluate and improve their effectiveness in primary care settings. One potential strategy is a hard stop, which requires health care providers to act on prompts before being able to continue further use of the EHR. However, we suspect that few health systems are willing to incorporate hard stops for preventive prompts in order to retain hard stops for critical safety concerns and not hinder visit flow; indeed, the providers in our study specifically requested soft alerts that allowed providers to ignore prompts. A second potential strategy is to incorporate multiple prompts within the EHR pathway to alert nurses and providers multiple times (and perhaps in various ways) about the recommended preventive services. However, multiple prompts could become irritating to providers. A third potential strategy is to incorporate providerpatient communication strategies coupled with provider prompts in order to overcome parental (or provider) vaccine hesitancy. A fourth potential strategy is to incorporate qualityimprovement based audit feedback and practice-improvement methods to make providers aware of missed opportunities for immunization. A recent study by Fiks et al<sup>15</sup> noted that a clinician decision-support provider prompt resulted in an increase in HPV<sub>1</sub> vaccination rates (though no increase in HPV<sub>2-3</sub> rates) and shorter time to complete the HPV vaccine series in the prompt versus control group. The Fiks et al study was based in a single hospital-based network of practices all using the same EHR, and their intervention also included quarterly individual and practice-level performance feedback reports about missed opportunities and immunization rates. For our study, we elected to ask practices to self-monitor their performance, and we encouraged, but did not require, practices to self-audit charts each month to assess missed opportunities, thinking that this method was more scalable. Unfortunately, few practices complied with these self-audits. A fifth potential strategy is to use incentives, such as pay for performance, to increase adherence to immunization prompts; however, to our knowledge, no study has evaluated such a combined strategy. It is possible that multiple practice-improvement methods are needed, in addition to provider prompts, to help practitioners respond to immunization prompts.

Finally, multiple strategies beyond a successful prompt-based intervention are needed to improve adolescent immunization rates.<sup>10,36</sup> Although many of these strategies have had only limited field testing with respect to adolescent immunization delivery, they include

patient reminder/recall, standing orders, audit feedback, and improved provider communication.

#### Strengths and Limitations

Study strengths include the use of a mixed methods study that incorporated qualitative interviews and a rigorous randomized controlled clinical trial, 2 independent PBRNs for generalizability, adequate sample size to detect even small effects of prompts, and a realworld intervention. Limitations include the limited number of practices (n = 24 practices before randomization) with an inability to control for some practice-based factors that might have affected missed opportunities or vaccination rates, the loss of one practice pair from the GR-PBRN, an inability to determine precisely the degree to which prompts resulted in increased discussions about immunizations, and high baseline meningococcal and Tdap immunization rates. Importantly, many practices had recently converted to EHRs, and it is possible that the overwhelming impact of using EHRs dampened immunization prompts' effects. Further, in most cases the alerts were not modifiable; they simply appeared as standard prompts on the screen. Finally, we were unable to measure provider discussions with patients beyond assessing parent refusals or requests for delaying vaccinations. Nevertheless, in our study, refusal rates were similar for intervention and control practices, so we do not believe that parent refusals contributed substantially to the lack of benefit of the immunization prompts.

#### Conclusions

Although provider prompts are recommended to improve immunization rates, in this study performed in both a local and national PBRN, provider prompts failed to improve adolescent immunization rates and generally failed to reduce missed opportunities for immunization. More rigorous practice-based changes are needed to improve rates.

#### Acknowledgments

A portion of this paper was presented at the 2014 Pediatric Academic Societies annual meeting, Vancouver, BC, May 3-6, 2014. This study was funded by the US Centers for Disease Control and Prevention (grant 5U011P000312). A nonoverlapping portion of the overall study was published in *Clinical Pediatrics* 2013;52:706-716. We appreciate the collaboration of the physicians and staff at the participating primary care practices. We also appreciate the thoughtful reviewer critiques, which improved the article substantially.

#### References

- Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1–62.
- US Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13–17 years—United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:685–693. [PubMed: 23985496]
- US Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13–17 years—United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:671–677. [PubMed: 22932301]
- US Centers for Disease Control and Prevention. Flu vaccination coverage, United States, 2012–13 influenza season. Available at: http://www.cdc.gov/flu/fluvaxview/coverage-1213estimates.htm. Accessed January 23, 2015.

- US Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years—United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:1117–1123. [PubMed: 21866084]
- Szilagyi PG, Albertin C, Humiston SG, et al. A randomized trial of the effect of centralized reminder/recall on immunizations and preventive care visits for adolescents. Acad Pediatr. 2013;13:204–213. [PubMed: 23510607]
- 7. Hambidge SJ. The challenge of reaching adolescents to promote health care. Acad Pediatr. 2013;13:184–185. [PubMed: 23680337]
- US Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007–2012, and postlicensure vaccine safety monitoring, 2006–2013—United States. MMWR Morb Mortal Wkly Rep. 2013;62:591–595. [PubMed: 23884346]
- 9. Task Force on Community Preventive Services Focus on Vaccine Preventable Disease. Available at: http://www.thecommunityguide.org/. Accessed January 23, 2015.
- Briss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. The Task Force on Community Preventive Services. Am J Prev Med. 2000;18(1 suppl):97–140.
- Santoli JM, Szilagyi PG, Rodewald LE. Barriers to immunization and missed opportunities. Pediatr Ann. 1998;27:366–374. [PubMed: 9648171]
- Szilagyi PG, Rodewald LE. Missed opportunities for immunizations: a review of the evidence. J Public Health Manag Pract. 1996;2:18–25. [PubMed: 10186652]
- 13. Kumar S, Aldrich K. Overcoming barriers to electronic medical record (EMR) implementation in the US healthcare system: a comparative study. Health Inform J. 2010;16:306–318.
- Fiks AG, Hunter KF, Localio AR, et al. Impact of electronic health record-based alerts on influenza vaccination for children with asthma. Pediatrics. 2009;124:159–169. [PubMed: 19564296]
- Fiks AG, Grundmeier RW, Mayne S, et al. Effectiveness of decision support for families, clinicians, or both on HPV vaccine receipt. Pediatrics. 2013;131:1114–1124. [PubMed: 23650297]
- Au L, Oster A, Yeh GH, et al. Utilizing an electronic health record system to improve vaccination coverage in children. Appl Clin Inform. 2010;1:221–231. [PubMed: 23616838]
- Fiks AG. Designing computerized decision support that works for clinicians and families. Curr Probl Pediatr Adolesc Health Care. 2011;41:60–88. [PubMed: 21315295]
- Bryan C, Boren SA. The use and effectiveness of electronic clinical decision support tools in the ambulatory/primary care setting: a systematic review of the literature. Inform Prim Care. 2008;16:79–91. [PubMed: 18713524]
- 19. Shojania KG, Jennings A, Mayhew A, et al. Effect of point-of-care computer reminders on physician behaviour: a systematic review. CMAJ. 2010;182:E216–E225. [PubMed: 20212028]
- Shojania KG, Jennings A, Mayhew A, et al. The effects of on-screen, point of care computer reminders on processes and outcomes of care. Cochrane Database Syst Rev. 2009;CD001096. [PubMed: 19588323]
- 21. Szilagyi PG, Rodewald LE, Humiston SG, et al. Reducing missed opportunities for immunizations. Easier said than done. Arch Pediatr Adolesc Med. 1996;150:1193–1200. [PubMed: 8904862]
- Sabnis SS, Pomeranz AJ, Amateau MM. The effect of education, feedback, and provider prompts on the rate of missed vaccine opportunities in a community health center. Clin Pediatr (Phila). 2003;42:147–151. [PubMed: 12659388]
- Sabnis SS, Pomeranz AJ, Lye PS, et al. Do missed opportunities stay missed? A 6-month followup of missed vaccine opportunities in inner city Milwaukee children. Pediatrics. 1998;101:E5.
- 24. Bundy DG, Persing NM, Solomon BS, et al. Improving immunization delivery using an electronic health record: the ImmProve project. Acad Pediatr. 2013;13:458–465. [PubMed: 23726754]
- 25. Gibson K, Szilagyi P, Swanger CM, et al. Physician perspectives on incentives to participate in practice-based research: a Greater Rochester Practice-Based Research Network (GR-PBRN) study. J Am Board Fam Med. 2010;23:452–454. [PubMed: 20616287]
- 26. Rogers EM. Diffusion of Innovations. 5th ed. New York, NY: Free Press; 2003.

- 27. Albright K, Gechter K, Kempe A. Importance of mixed methods in pragmatic trials and dissemination and implementation research. Acad Pediatr. 2013;13:400–407. [PubMed: 24011744]
- Humiston SG, Serwint JR, Szilagyi PG, et al. Increasing adolescent immunization rates in primary care: strategies physicians use and would consider implementing. Clin Pediatr (Phila). 2013;52:710–720. [PubMed: 23580625]
- 29. Task Force on Community Preventive Services. Vaccine-preventable diseases: improving vaccination coverage in children, adolescents, and adults. A report on recommendations from the Task Force on Community Preventive Services. MMWR Recomm Rep. 1999;48(RR-8):1–15.
- Rodewald L, Maes E, Stevenson J, et al. Immunization performance measurement in a changing immunization environment. Pediatrics. 1999;103(4 pt 2):889–897. [PubMed: 10103327]
- 31. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics. 2000;56:645–646. [PubMed: 10877330]
- 32. National, state, and local area vaccination coverage among adolescents aged 13–17 years—United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59:1018–1023. [PubMed: 20724968]
- Wasserman RC. Electronic medical records (EMRs), epidemiology, and epistemology: reflections on EMRs and future pediatric clinical research. Acad Pediatr. 2011;11:280–287. [PubMed: 21622040]
- 34. Fiks AG, Grundmeier RW, Biggs LM, et al. Impact of clinical alerts within an electronic health record on routine childhood immunization in an urban pediatric population. Pediatrics. 2007;120:707–714. [PubMed: 17908756]
- Dombkowski KJ, Davis MM, Cohn LM, et al. Effect of missed opportunities on influenza vaccination rates among children with asthma. Arch Pediatr Adolesc Med. 2006;160:966–971. [PubMed: 16953021]
- 36. Szilagyi PG, Rand CM, McLaurin J, et al. Delivering adolescent vaccinations in the medical home: a new era? Pediatrics. 2008;121(suppl 1):S15–S24. [PubMed: 18174317]



#### Figure.

Flow diagram showing intervention (prompt) and control practices and subjects for chart reviews. Peds indicates pediatric practice; FM, family medicine practice; and CHC, community health center. \*The CHC practice pair was excluded because the intervention practice was unable to perform prompts. °A random sample of adolescents who made a visit during the 12-month baseline or 12-month intervention period was selected for chart review; the same number of medical charts was reviewed for each time period (ie, n = 3,520 for the baseline period and n = 3,520 for the intervention period).

Table 1.

Baseline Practice and Patient Characteristics and Preventive Care Visit Rates by Randomization Group

CharacteristicIntervationControl $F^*$ IntervationControl $F^*$ Practice Characteristics $S_0$ of practices $S_0$ $S_0$ $S_0$ $S_0$ $S_0$ $S_0$ $S_0$ No. of practices by location $41$ $41$ $41$ $K_1$ $S_0$ $S_0$ $S_0$ $S_0$ $S_0$ $S_0$ No. of practices by location $41$ $41$ $K_1$ $S_0$		•	<b>GR-PBRN</b>		•	CORNET	
Practice Characteristics         5         5         5         6         6         NA           No. of practices         No. of practices         4.1         4.1         NA         60         60         NA           No. of practices by location         4.1         4.1         NA         60         60         NA           No. of practices by location         1         1         1         0         6         6         NA           No. of practices by location         1         1         1         0         6         6         8           No. of practices by location         1         1         1         0         0         0         9         9           No. of practices by location         1         1         1         1         1         1         9	Characteristic	Intervention	Control	$P^{*}$	Intervention	Control	$P^*$
No. of practices         5         5         6         6           No. of practices by location         4.1         1         NA         60         60         NA           No. of practices by location         1         4.1         NA         60         60         NA           No. of practices by location         1         1         1         0         6         6         NA           No. of practices by location         1         1         1         1         0         0         0         NA           Suburban         1         1         1         1         1         0         <	Practice Characteristics						
No. of pediatrics/family medicine practices $4.1$ $4.1$ $NA$ $60$ $60$ $NA$ No. of practices by location       1       1       1 $6$ $6$ $NA$ Urban       0       0       0       0 $6$ $6$ $6$ $NA$ No. of practices by location       4       4 $1$ $1$ $6$ $6$ $6$ $NA$ Suburban       4 $1$ $1$ $1$ $1$ $0$ $0$ $0$ $0$ $0$ $0$ $NA$ Suburban $4$ $1$ $1$ $1$ $1$ $1$ $1$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $0$ $1$	No. of practices	5	5		9	9	
No. of practices by location       NA       NA         Urban       Urban       0       6       6       6         Suburban       1       1       0       0       0       0       1         Suburban       4       4       0       0       0       0       0       0       0       0         Suburban       1       1       1       0	No. of pediatrics/family medicine practices	4/1	4/1	NA	6/9	6/0	NA
Urban         0         0         0         6         6           Suburban         4         4         0         <	No. of practices by location			NA			NA
Suburban         4         4         0         0         0           Rual         1         1         1         0         55         13.375 (8.499)         55         5500 (1,870)         55         13.375 (8.499)         55         5500 (1,870)         55         13.455 (747)         2.5000 (1,870)         55         14.45         5500 (1,870)         55         14.45         5500 (1,870)         55         14.45         5500 (1,870)         55         14.45         5500 (1,870)         55         14.45         5500 (1,870)         55         14.45         5500 (1,870)         55         14.45         5500 (1,870)         55         14.45         5500 (1,870)         55         14.45         5500 (1,870)         5500 (1,870)         5500 (1,870)<	Urban	0	0		9	9	
Rural         1         1         0         0         0           Average size, mean (SD) <sup><math>\uparrow</math></sup> Average size, mean (SD) <sup><math>\uparrow</math></sup> 7.125 (5,808)         9.125 (2,462)         63         8.029 (4,249)         13.375 (8,499)         59           All ages         11-18 y         2.600 (1,980)         4,450 (5,020)         55         1,815 (7,47)         2.500 (1,870)         37           House         Patient Characteristics         2.600 (1,980)         4,450 (5,020)         55         1,815 (7,47)         2.500 (1,870)         37           From Baseline Characteristics         2.600 (1,980)         4,450 (5,020)         55         1,815 (7,47)         2.500 (1,870)         37           From Baseline Characteristics         800         800         800         960         960         960           No of patients by insurance type, n (%)         117 (1,5%)         159 (20)         333 (35)         279 (29)         36 <td>Suburban</td> <td>4</td> <td>4</td> <td></td> <td>0</td> <td>0</td> <td></td>	Suburban	4	4		0	0	
Average size, mean $(SD)^{\dagger}$ Average size, mean $(SD)^{\dagger}$ Average size, mean $(SD)^{\dagger}$ Signal such vector second signal sucod second second second second second second second second secon	Rural	1	1		0	0	
All ages $7.125 (5.808)$ $9.125 (2.462)$ $53$ $8.029 (4.249)$ $13.375 (8.499)$ $59$ $11-18y$ $2.600 (1.980)$ $4.450 (5.020)$ $55$ $1.815 (747)$ $2.500 (1.870)$ $87$ Adolescent Patient Characteristics         From Baseline Characteristics $800$ $800$ $960$	Average size, mean (SD) $^{\not  au}$						
11-18 y         2.600 (1.980)         4.450 (5.020)         55         1.815 (747)         2.500 (1.870)         87           Adolescent Patient Characteristics         From Baseline Characteristics         960         960         960         44           From Baseline Characteristics         800         800         900         960         960         960         44           No. of patients by insurance type, n (%)         117 (15%)         159 (20)         589 (61)         665 (63)         44           Private         117 (15%)         159 (20)         834 (35)         279 (29)         44           None/military         14 (2%)         365 (75)         334 (35)         776 (39)         86           None/military         14 (2%)         365 (75)         334 (35)         76 (8)         86           None/military         14 (2%)         365 (75)         334 (35)         776 (29)         86           None/military         14 (2%)         36 (76)         334 (35)         76 (39)         86         960           None/military         14 (2%)         36 (76)         37 (49)         76 (8)         86         96         96           Race, n (%) <sup>‡</sup> NA         NA         NA         NA         19	All ages	7,125 (5,808)	9,125 (2,462)	.63	8,029 (4,249)	13,375 (8,499)	.59
Adolescent Patient Characteristics       800       960       960       960         From Baseline Chart Review       No. of patients       960       960       960       960         No. of patients by insurance type, n (%) $001$ $001$ $001$ $001$ $001$ Private $117 (15\%)$ $159 (20)$ $589 (61)$ $605 (63)$ $001$ Public $006/military$ $065 7(6)$ $334 (53)$ $279 (29)$ $001$ None/military $14 (2\%)$ $36 (5)$ $334 (53)$ $270 (29)$ $001$ None/military $14 (2\%)$ $399 (50)$ $85$ $473 (4)$ $76 (8)$ $001$ Race, $n (\%)^{2}$ NA       NA       NA       NA $001$ $001$ $001$ Race, $n (\%)^{2}$ NA       NA       NA       NA $001$ $001$ $001$ $001$ Back, non-Hispanic $001$ $001$ $001$ $001$ $001$ $001$ $001$ $001$ $001$ $001$ $001$ $001$ $001$ $001$ $001$ $001$	11–18 y	2,600 (1,980)	4,450 (5,020)	.55	1,815 (747)	2,500 (1,870)	.87
From Baseline Chart Review       800       800       800       960	Adolescent Patient Characteristics						
No. of patients         No. of patients         800         800         960	From Baseline Chart Review						
Patients by insurance type, $n$ (%)       <       <       <       <       <       <       < <td>No. of patients</td> <td>800</td> <td>800</td> <td></td> <td>096</td> <td>096</td> <td></td>	No. of patients	800	800		096	096	
Private $117(15\%)$ $159(20)$ $589(61)$ $605(53)$ Public $669(84\%)$ $605(76)$ $334(35)$ $279(29)$ None/military $14(2\%)$ $36(5)$ $334(35)$ $279(29)$ None/military $14(2\%)$ $36(5)$ $37(4)$ $76(8)$ Reace, $n(\%)^{4}$ $NA$ $NA$ $NA$ $NA$ $76(4)$ $86$ White, non-Hispanic $NA$ $NA$ $NA$ $NA$ $76(49)$ $86$ Black, non-Hispanic $14(2\%)$ $86(36)$ $345(36)$ $500$ $946(39)$ $506(38)$ $345(36)$ Hispanic $NA$ $NA$ $NA$ $NA$ $NA$ $191(20)$ $916(9)$ $916(9)$ $916(9)$ Other, non-Hispanic $116(1)$ $116(1)$ $1105(11)$ $1186(19)$ $916(9)$ $916(9)$ $916(19)$ Missing $1100$ $1100$ $1100$ $1100(11)$ $1100(11)$ $1100(11)$ $1100(11)$ Missing $1100$ $1100$ $1100$ $1100(11)$ $1100(11)$ $910(21)$ $1100(11)$ Missing $1100$ $1100$ $1100$ $1100(11)$ $1100(11)$ $1100(11)$	Patients by insurance type, n (%)			<.001			44.
Public $669 (84\%)$ $665 (76)$ $334 (35)$ $279 (29)$ None/military $14 (2\%)$ $36 (5)$ $37 (4)$ $76 (8)$ Female patients, $n (\%)$ $393 (49\%)$ $399 (50)$ $85$ $473 (49)$ $76 (8)$ Race, $n (\%)$ $393 (49\%)$ $399 (50)$ $85$ $473 (49)$ $468 (49)$ $86$ White, non-HispanicNANANA $86 (49)$ $86$ Black, non-Hispanic $14 (2\%)$ $86 (38)$ $347 (35)$ $191 (20)$ Hispanic $116 (10)$ $106 (11)$ $186 (19)$ $96 (38)$ $345 (36)$ Other, non-Hispanic $116 (10)$ $105 (11)$ $186 (19)$ $96 (6)$ $39 (4)$ Missing $89 (9)$ $89 (9)$ $199 (21)$ $110 (20)$ Patients with preventive care visit during study period, $n (\%)$ $626 (78)$ $630 (80)$ $50 (72)$ $111 (20)$	Private	117 (15%)	159 (20)		589 (61)	605 (63)	
None/military $14 (2\%)$ $36 (5)$ $37 (4)$ $76 (8)$ Female patients, $n (\%)$ Female patients, $n (\%)$ $393 (49\%)$ $399 (50)$ $35 (49)$ $468 (49)$ $36 (49)$ Race, $n (\%)$ $(\%)$ $393 (49\%)$ $399 (50)$ $35 (49)$ $468 (49)$ $36 (49)$ $36 (49)$ Race, $n (\%)$ $(\%)$ $NA$ NANA $A73 (49)$ $468 (49)$ $36 (19)$ White, non-Hispanic $14 (2\%)$ $NA$ NA $NA$ $A73 (35)$ $191 (20)$ Black, non-Hispanic $14 (2\%)$ $366 (38)$ $345 (36)$ $345 (36)$ Hispanic $105 (11)$ $105 (11)$ $186 (19)$ Other, non-Hispanic $105 (11)$ $105 (11)$ $186 (19)$ Missing $89 (9)$ $89 (9)$ $199 (21)$ Patients with preventive care visit during study period, $n (\%)$ $626 (78)$ $639 (80)$ $50 (72)$ $50 (72)$	Public	669 (84%)	605 (76)		334 (35)	279 (29)	
Female patients, n (%)Female patients, n (%)393 (49%)399 (50) $.85$ $473 (49)$ $468 (49)$ $.86$ Race, n (%) $^{4}$ NANANANA $< 01$ White, non-Hispanic $340 (35)$ $191 (20)$ $< 01$ Black, non-Hispanic $346 (38)$ $345 (36)$ $345 (36)$ Hispanic $00$ $105 (11)$ $186 (19)$ Other, non-Hispanic $00$ $00 (6)$ $39 (4)$ Missing $89 (9)$ $199 (21)$ Patients with preventive care visit during study period, n (%) $626 (78)$ $639 (80)$ $50$ $694 (72)$	None/military	14 (2%)	36 (5)		37 (4)	76 (8)	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Female patients, n (%)	393 (49%)	399 (50)	.85	473 (49)	468 (49)	.86
White, non-Hispanic       340 (35)       191 (20)         Black, non-Hispanic       366 (38)       345 (36)         Hispanic       105 (11)       186 (19)         Other, non-Hispanic       60 (6)       39 (4)         Missing       89 (9)       199 (21)         Patients with preventive care visit during study period, n (%)       626 (78)       639 (80)       50       694 (72)       11	Race, $n (\%)^{\ddagger}$	NA	NA	NA			<.01
Black, non-Hispanic       366 (38)       345 (36)         Hispanic       105 (11)       186 (19)         Other, non-Hispanic       60 (6)       39 (4)         Missing       89 (9)       199 (21)         Patients with preventive care visit during study period, n (%)       626 (78)       639 (80)       .50       808 (84)       694 (72)       .11	White, non-Hispanic				340 (35)	191 (20)	
Hispanic       105 (11)       186 (19)         Other, non-Hispanic       60 (6)       39 (4)         Missing       89 (9)       199 (21)         Patients with preventive care visit during study period, n (%)       626 (78)       639 (80)       .50       808 (84)       694 (72)       .11	Black, non-Hispanic				366 (38)	345 (36)	
Other, non-Hispanic         60 (6)         39 (4)           Missing         89 (9)         199 (21)           Patients with preventive care visit during study period, n (%)         626 (78)         639 (80)         .50         808 (84)         694 (72)         .11	Hispanic				105 (11)	186 (19)	
Missing         89 (9)         199 (21)           Patients with preventive care visit during study period, n (%)         626 (78)         639 (80)         .50         808 (84)         694 (72)         .11	Other, non-Hispanic				60 (6)	39 (4)	
Patients with preventive care visit during study period, n (%) 626 (78) 639 (80) .50 808 (84) 694 (72) .11	Missing				(6) 68	199 (21)	
	Patients with preventive care visit during study period, n (%)	626 (78)	639 (80)	.50	808 (84)	694 (72)	H.

Acad Pediatr. Author manuscript; available in PMC 2021 August 05.

 $\stackrel{*}{P}$  values from conditional logistics regression, conditioning on matched practices.

# Author Manuscript

Author Manuscript

 $\dot{r}P$  value from paired *t* test.

<sup>4</sup>/kace was missing in >75% of cases from the GR-PBRN (so is not presented here) and was also missing in 15% of cases from CORNET (recoded as "missing").

Szilagyi et al.

## Table 2.

Immunization Rates at Baseline and End of Study Period by Study Group Stratified by  $PBRN^*$ 

	Baselin	ы	End of Study	/ Period		
Immunization	Intervention, n (%)	Control, n (%)	Intervention, n (%)	Control, n (%)	aOR <sup>†</sup> (95% CI)	Ρ
GR-PBRN						
Tdap	760 (95)	746 (93)	783 (98)	767 (96)	1.44 (0.82–2.56)	.21
MCV4	709 (89)	701 (88)	741 (93)	728 (91)	1.15 (0.64–2.05)	.65
$HPV_1$	251 (64)	268 (67)	253 (64)	286 (68)	0.92 (0.60–1.40)	.70
$HPV_2$	229 (58)	249 (62)	234 (59)	261 (62)	1.01 (0.57–1.77)	96.
$HPV_3$	199 (51)	205 (51)	201 (51)	221 (53)	0.93 (0.64–1.34)	.70
MCV4 and Tdap	678 (85)	665 (83)	734 (92)	704 (88)	1.39 (0.77–2.51)	.28
Seasonal influenza	252 (32)	243 (30)	279 (35)	282 (35)	0.93 (0.69–1.25)	.78
CORNET						
Tdap	877 (91)	811 (84)	904 (94)	842 (88)	1.16(0.68 - 1.99)	.59
MCV4	882 (92)	803 (84)	908 (95)	844 (88)	1.08 (0.82–1.41)	.59
HPV₁ <i>‡</i>	363 (77)	317 (68)	392 (82)	358 (75)	0.96 (0.59–1.56)	.87
$HPV_2$	313 (66)	265 (57)	338 (71)	286 (60)	1.06 (0.68–1.66)	.79
$HPV_3$	229 (48)	207 (44)	237 (50)	200 (42)	1.13 (0.68–1.88)	.64
MCV4 and Tdap	839 (87)	749 (78)	889 (93)	793 (83)	1.35 (0.92–1.97)	.13
Seasonal influenza	472 (49)	410 (43)	457 (48)	421 (44)	$0.89\ (0.69 - 1.16)$	.54

Acad Pediatr. Author manuscript; available in PMC 2021 August 05.

PBRN indicates practice-based research network; aOR, adjusted odds ratio; CI, confidence interval; GR-PBRN, Greater Rochester Practice-Based Research Network; CORNET, Continuity Clinic Research Network; Tdap, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; MCV4, meningococcal vaccine; and HPV, human papillomavirus vaccine (HPV1, first vaccination in series, etc).

Denominators are n = 800 (GR-PBRN) or n = 960 (CORNET) except for HPV vaccine, where the denominators are for female subjects only. Denominators of female subjects for HPV calculations are: GR-PBRN-baseline (intervention = 393, control = 399) and study end (intervention = 397, control = 420); CORNET-baseline (intervention = 473, control = 478, con Based on 160 randomly selected chart reviews per practice at baseline and again at the end of the study. The GR-PBRN included 5 practice pairs; the CORNET PBRN included 6 practice pairs. 476). \*

<sup>4</sup> a OR is odds of change in outcomes (immunization rates) for intervention versus odds of change in outcomes (immunization rates) for control practices, expressed as odds ratio. Odds ratios come from robust multilevel mixed-effect logistic regression models with covariates pair assignment, study time period, intervention assignment, and an interaction between time and intervention assignment.

 $^{t}_{\mathrm{HPV}}$  assessed for female subjects only.

Author Manuscript

## Table 3.

Hazard Ratios<sup> $\pi$ </sup> and 95% CI for Intervention vs. Control Female Subjects–Time From Eligibility for HPV (or Study Start for All Vaccinations Combined) to Receiving Missing HPV Vaccine Doses (or Receiving All 3 Recommended Doses) $^*$ 

		Η	$\mathbf{R}^{\mu}$	
Study Group	HPV1*	$\mathrm{HPV}_{2}^{*}$	HPV3*	3 HPV Vaccines $^{\dagger}$
GR-PBRN	0.86 (0.52–1.43)	2.24 (1.21–4.16)	1.25 (0.61–2.53)	0.94 (0.60–1.49)
CORNET	0.85 (0.57–1.27)	1.24 (0.69–2.23)	1.32 (0.66–2.64)	1.21 (0.83–1.77)

HPV indicates human papillomavirus vaccine (HPV1, first vaccination in series, etc); HR, hazard ratio; GR-PBRN, Greater Rochester Practice-Based Research Network; and CORNET, Continuity Clinic Research Network. \* Time from eligibility to receipt of HPV vaccine dose or doses. Note that all female subjects were eligible for HPV1 except for those who already had the first dose by the start of the study. Analyses for HPV2 and HPV3 receipt accounted for the recommended spacing intervals between doses.

 ${}^{\dagger}$ Time from start of study period to being fully vaccinated with 3 doses of HPV vaccine.

HPV2) means that the intervention group's HR increased 124% over study periods compared to the control group's HR. The second to the last column assesses the interval between HPV2 and HPV3 and is The hazard function is the chance that a subject will have an event at a specific time, given that the individual did not already have the event. The HR is the interaction term. For example, a HR of 2.24 (for limited to adolescents who received HPV2. The last column assesses the time from the start of the intervention to completion of HPV series.

<b>_</b>
- 12
~
_
_
_
-
$\mathbf{c}$
$\sim$
_
_
-
_
2
0
a
lar
lan
lan
lanu
lanu
lanu
lanus
lanus
lanus
lanusc
lanusc
lanusci
lanuscr
lanuscri
lanuscri
lanuscrip
lanuscrip
<b>Nanuscript</b>

Missed Opportunities and Refusal Rates by Vaccine for Intervention Versus Control Practices During Baseline and Intervention Period by PBRN

	Baseli	ne	Intervention	r Period		
Characteristic	Intervention, n (%)	Control, n (%)	Intervention, n (%)	Control, n (%)	Incident Risk Ratio (95% CI)	Ρ
GR-PBRN						
Visits with missed opportunities during the intervention year $^{st}$						
HPV (girls)	184/552 (33)	166/528 (31)	165/606 (27)	173/567 (31)	0.82 (0.72–0.94)	.005
Influenza	194/527 (37)	179/514 (35)	192/538 (36)	188/516 (36)	0.92 (0.79–1.06)	.26
Any vaccine	552/584 (95)	535/568 (94)	598/659 (91)	558/616 (91)	1.01 (0.97–1.05)	.52
Patients with any missed opportunity during the intervention year	779 (98)	764 (96)	765 (96)	752 (94)	0.84 (0.41–1.72)	.64
Patients who refused any vaccine during the year $\check{r}$	51 (6)	59 (7)	121 (15)	91 (11)	1.64 (0.79–3.41)	.18
CORNET						
Visits with missed opportunities during the intervention year $^{*}$						
HPV (girls)	163/632 (26)	215/749 (29)	131/472 (28)	172/577 (30)	1.00 (0.87–1.15)	86.
Influenza	218/549 (40)	273/707 (39)	174/415 (42)	211/556 (38)	1.00 (0.80–1.24)	66.
Any vaccine	556/678 (82)	753/821 (92)	388/503 (77)	591/634 (93)	0.99 (0.93–1.05)	69.
Patients with any missed opportunity during the intervention year	833 (87)	883 (93)	699 (78)	801 (87)	0.92 (0.51 - 1.66)	LL.
Patients who refused any vaccine during the intervention year ${}^{\!\!\!\!/}$	128 (13)	40 (4)	134 (14)	41 (4)	1.03 (0.36–2.97)	96.
PBRN indicates practice-based research network; CI, confidence interv	al; GR-PBRN, Greater F	Rochester Practice-	Based Research Networ	k; CORNET, Conti	nuity Clinic Research Network; T	lap, tetanı

Acad Pediatr. Author manuscript; available in PMC 2021 August 05.

s toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; MCV4, meningococcal vaccine; and HPV, human papillomavirus vaccine.

\* Numerator is number of visits that involved a missed opportunity; denominator, total number of visits during the year when adolescents were eligible for a vaccine. The adjusted incidence-rate ratio is shown.

 $\stackrel{f}{
m \ell}$  Refusal for any vaccine (MCV4, Tdap, HPV, or influenza).